Latest On TG Therapeutics, Inc (TGTX):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-06 07:44 EST | News | TG Therapeutics' Stock Surge: Exploring The Factors And Exercising Caution (Rating Upgrade) | N/A |  |
| 2023-05-02 02:37 EST | News | TG Therapeutics jumps 19% to hit 52-week high after Q1 beat (update) | N/A | |
| 2023-05-01 14:23 EST | News | TG Therapeutics GAAP EPS of -$0.28 beats by $0.07, revenue of $7.8M beats by $4.42M | N/A | |
| 2023-05-01 14:23 EST | News | TG Therapeutics slips despite Q1 beat | N/A | |
| 2023-05-01 14:22 EST | News | TG Therapeutics, Inc. (TGTX) Q1 2023 Earnings Call Transcript | N/A | |
About TG Therapeutics, Inc (TGTX):
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available read more...and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. The company is headquartered in New York, New York.
General
- Name TG Therapeutics, Inc
- Symbol TGTX
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 272
- Last Split Factor100:5625
- Last Split Date2012-04-30
- Fiscal Year EndDecember
- IPO Date1995-12-14
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.tgtherapeutics.com
Valuation
- Price/Sales (Trailing 12 Mt.) 36580.51
- Price/Book (Most Recent Quarter) 13.05
- Enterprise Value Revenue 40882.96
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$2.06
- Next Year EPS Estimate -$0.80
- Next Quarter EPS Estimate -$0.50
- Operating Margin -179996%
- Return on Assets -43%
- Return on Equity -100%
- Revenue 152000
- Earnings Per Share -$1.96
- Revenue Per Share $0
- Gross Profit 152000
- Quarterly Earnings Growth 0%
Highlights
- Market Capitalization 6.47 billion
- EBITDA -158616992
- PE Ratio 37.85
- Analyst Target Price $75.33
- Book Value Per Share $4.00
Share Statistics
- Shares Outstanding 137.81 million
- Shares Float 120.36 million
- % Held by Insiders 713%
- % Held by Institutions 67.24%
- Shares Short 11.84 million
- Shares Short Prior Month 11.76 million
- Short Ratio 8
- Short % of Float 10%
- Short % of Shares Outstanding 8%
Technicals
- Beta 2.13
- 52 Week High $56.74
- 52 Week Low $7.12
- 50 Day Moving Average 46.97
- 200 Day Moving Average 37.82
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
TG Therapeutics, Inc (TGTX) Dividend Calendar:
TG Therapeutics, Inc (TGTX) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
TG Therapeutics, Inc (TGTX) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
TG Therapeutics, Inc (TGTX) Chart:
TG Therapeutics, Inc (TGTX) News:
Below you will find a list of latest news for TG Therapeutics, Inc (TGTX) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
TG Therapeutics, Inc (TGTX) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest TGTX Trades:
TG Therapeutics, Inc (TGTX) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-05 | 8-K (Current report) | |
| 2020-09-11 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-10 | 8-K (Current report) | |
| 2020-08-10 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-07-20 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-02 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-07-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-24 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-24 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-24 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-24 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-24 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-24 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-24 | 8-K (Current report) | |
| 2020-06-10 | SC 13G (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-06-10 | SC 13G/A (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-05-29 | PX14A6G (Notice of exempt solicitation submitted by non-management) | |
| 2020-05-18 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-05-18 | 8-K (Current report) | |
TG Therapeutics, Inc (TGTX) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of TG Therapeutics, Inc (TGTX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 713%
Institutional Ownership: 6724%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-09-09 | RA CAPITAL MANAGEMENT, L.P. | 10% Share Holder | Sell | 158,589.00 | 25.81 | 4,092,738.04 | 12,629,868.00 | |
| 2020-07-16 | Sean A Power | CFO, Secretary and Treasurer | Buy | 50,000.00 | 433,338.00 | | ||
| 2020-07-16 | Sean A Power | CFO, Secretary and Treasurer | Buy | 200,000.00 | 633,338.00 | | ||
| 2020-06-22 | WILLIAM JAMES KENNEDY | Director | Buy | 15,000.00 | 109,633.00 | | ||
| 2020-06-22 | DANIEL HUME | Director | Buy | 15,000.00 | 134,507.00 | | ||
| 2020-06-22 | MICHAEL S WEISS | CEO and President | Buy | 1,556,029.00 | 14,434,214.00 | | ||
| 2020-06-22 | Kenneth Hoberman | Director | Buy | 15,000.00 | 158,953.00 | | ||
| 2020-06-22 | Yann Echelard | Director | Buy | 15,000.00 | 159,116.00 | | ||
| 2020-06-22 | Laurence N Charney | Director | Buy | 15,000.00 | 160,997.00 | | ||
| 2020-06-22 | Sagar Lonial | Director | Buy | 65,000.00 | 65,000.00 | | ||
| 2020-06-17 | WILLIAM JAMES KENNEDY | Director | Sell | 7,745.00 | 18.27 | 141,501.15 | 94,633.00 | |
| 2019-09-17 | WILLIAM JAMES KENNEDY | Director | Buy | 27,048.00 | 102,378.00 | | ||
| 2019-09-17 | DANIEL HUME | Director | Buy | 27,048.00 | 119,507.00 | | ||
| 2019-09-17 | Kenneth Hoberman | Director | Buy | 27,048.00 | 143,953.00 | | ||
| 2019-09-17 | Yann Echelard | Director | Buy | 27,048.00 | 144,116.00 | | ||
| 2019-09-17 | Laurence N Charney | Director | Buy | 27,048.00 | 145,997.00 | | ||
| 2019-07-01 | Sean A Power | CFO, Secretary and Treasurer | Sell | 17,654.00 | 8.47 | 149,529.38 | 383,338.00 | |
| 2019-06-26 | MICHAEL S WEISS | CEO and President | Buy | 50,000.00 | 7.04 | 351,750.00 | 12,878,185.00 | |
| 2019-06-13 | MICHAEL S WEISS | CEO and President | Buy | 1,179,380.00 | 12,828,185.00 | | ||
| 2019-01-02 | Sean A Power | CFO, Secretary and Treasurer | Sell | 37,275.00 | 4.13 | 153,945.75 | 400,992.00 | |